105 results about "Myofibroblast" patented technology

This invention relates to inhibition of αv integrins, especially αvβ3 and αvβ6 integrins, by specific antagonists, preferably non-peptidic antagonists, related compounds and compounds with comparable specificity, that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g., collagens, TIMP-1) and cytokines (e.g., CTGF) by activated hepatic stellate cells/myofibroblasts, activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent, mitigate or even reverse development of advanced fibrosis, such as fibrosis/cirrhosis of the liver and fibrosis of other organs, such as lungs, kidneys, intestine, pancreas, skin and arteries.

Composition for preventing the formation of new scar, e.g. myofibroblast, having BMP-7 polypeptide is disclosed. The composition for preventing the formation of scar includes an effective amount of BMP-7 (Bone Morphogenic Protein-7) polypeptide of sequence 1. The effective amount is 50 ng/ml-50 μg/ml or 0.1 ng-1 μg/kg by weight and the scar is a corneal scar.

Described is a scaffold that is strong enough to resist forces that exist inside a body, while possessing biocompatible surfaces. The scaffold is formed of a layer of mesh (e.g., Stainless Steel or Nitinol) that is tightly enclosed by a multi-layer biological matrix. The biological matrix can include three layers, such a first layer (smooth muscle cells) formed directly on the metal mesh, a second layer (fibroblast/myofibroblast cells) formed on the first layer, and a third layer (endothelial cells) formed on the second layer. The scaffold can be formed to operate as a variety of tissues, such as a heart valve or a vascular graft. For example, the mesh and corresponding biological matrix can be formed as leaflets, such that the scaffold is operable as a tissue heart valve.

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue.

The invention discloses RNA and application of RNA in diseases of a cardiovascular system. According to RNA, the nucleotide sequence of RNA is a sequence 3 in a sequence table. The invention further provides a gene,encoding RNA. The nucleotide sequence of the gene of RNA is a sequence 4 in the sequence table. The experiment of the invention shows that RNA and the application of RNA in the diseases of the cardiovascular system find that by an induction of isoproterenol (ISO), RNAi method Knock down IHP-55 is used in neonatal rat cardiac fibroblasts to obviously promote proliferation of cardiac fibroblasts; ISO induced activation and kinase activity of P38MAPK can be enhanced in the Knock-down HIP-55 cardiac fibroblasts; and HIP-55 is a new protein which has a protective effect on cardiac fibrosis, and provides a new target for clinical diagnosis, treatment and new medicament development.

The invention discloses an injectable myocardial tissue engineering product used for treating myocardial infarction, in particular, the product applies OPF hydrogel as a scaffold and carries one or more different angiogenic growth factors such as bFGF, PDGF-BB, VEGF and the like, and the repair effect of the product on myocardial infarction regions is observed after the product is injected and transplanted into the certain regions of an animal myocardial infarction model. The product built by the scaffold can promote generation of myocardial capillary and arteriola, enhance generation of myofibroblast, promote regeneration of the myocardial tissues, increase the ventricular wall thickness of the infarction regions, reshape the original ventricle and improve the cardiac function. The invention is simple in operating process and mild in implementation conditions, provides a new product for the myocardial tissue engineering and is of great significance in the development of clinically treating heart diseases by tissue-engineered myocardium.

The invention relates to a constitution and preparing method of a traditional Chinese medicine composition and application thereof to preparation of drugs for treating pulmonary fibrosis diseases. The composition is composed of radix astragali, radix codonopsis, radix ophiopogonis, fructus schizandrae, radix notoginseng, thunberg fritillary bulb, rhizoma anemarrhenae and licorice roots. The composition can regulate the expression of short-chain non-coding RNA (miRNAs) and long-chain non-coding RNA (incRNA), and can protect alveolar epithelial cells and interfere with the activity of myofibroblasts, so that the process of pulmonary fibrosis can be inhibited. Therefore, the composition is expected to be well applied to preparation of drugs for treating pulmonary fibrosis diseases.

Provided herein are compositions, methods, systems, and kits for wound healing. As shown herein, CCN2/CTGF stimulated mesenchymal progenitor cells can form αSMA⁻ fibroblasts. Further, TGFβ was shown to stimulate further differentiation of αSMA⁻ fibroblasts to myofibroblasts associated with fibrosis. One aspect provides a composition including CCN2/CTGF and a TGFβ inhibitor, a P38 inhibitor, or a tyrosine kinase inhibitor. Another aspect provides a method of treating tissue wounds with CCN2/CTGF-containing compositions. Also provided are systems and kits for wound healing. Also provided are methods for forming αSMA⁻ fibroblasts mesenchymal progenitor cells.

The invention provides an inhibitor for P4HB gene expression. The inhibitor is a siRNA molecule of a nucleotide sequence shown by SEQ ID NO. 1. According to the inhibitor provided by the invention, the nucleotide sequence of the siRNA molecule has complementary combination with mRNA generated by the P4HB gene expression, so that the P4HB gene at a target site is prevented from being expressed as protein, the P4HB gene is kept silent, and a purpose of inhibiting the P4HB gene expression can be achieved. The invention also provides application of the inhibitor in preparing a drug for preventing or treating liver cancer. The inhibitor provided by the invention has complementary combination with mRNA generated by the P4HB gene expression, so that the P4HB gene is kept silent, the epithelial-myofibroblast transdifferentiation (EMT) can play an opposite effect. Meanwhile, the silence of P4HB can inhibit in vivo tumor formation of the liver cancer cells.

The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.

The invention belongs to the technical field of biomedical treatment and in particular relates to an application of a protein P311 to treatment of skin wounds. The new specific regulatory protein P311 is discovered by regulating myofibroblast used in wound healing. The discovered protein P311 provides a new treatment strategy for promoting wound healing and preventing scar formation, brings good news for patients with skin wounds, such as burn patients, diabetic foot patients and surgical patients, and has extensive application and market prospects.

The invention discloses application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and/ or treating lung inflammation. The dipyridamole can inhibit the conversion of fibroblasts into myofibroblasts; meanwhile, the dipyridamole can also improve the respiratory function of a bleomycin-induced pulmonary fibrosis model rat, reduce the inflammatory infiltration of lung tissues and reduce the pathological states such as fibroblast proliferation and collagen accumulation in the lung tissues; and the dipyridamole has relatively high bonding strength with a 3CL enzyme as a pneumonia target triggered by a novel coronavirus in 2019 years, and has relatively high inhibitory activity on the 3CL enzyme of the coronavirus and a Vero E6 cell infected by the coronavirus, indicating that the dipyridamole has the effects of preventing and treating pulmonary fibrosis and pneumonia triggered by the novel coronavirus in 2019 years, and can be preparedinto a pneumonia medicine for application.

Methods of inhibiting lipofibroblast to myofibroblast transdifferentiation in a mammal are disclosed comprising administering a PPAR gamma ligand when said mammal is exposed to a hyperoxic condition.

Provided are: a targeting molecule targeting a target cell which is selected from the group consisting of a stellate cell, a myofibroblast, a cancer-associated fibroblast, a tumor cell and a cell expressing STRA6, said targeting molecule being selected from the group consisting of (1) a peptide containing an amino acid sequence in the cell-binding region of RBP, (2) a variant peptide of the aforesaid peptide (1), said variant peptide having a comparable targetability to peptide (1), and (3) a peptide mimetic having a comparable targetability to peptide (1) or peptide (2); a targeting agent, a carrier, a complex and a medicinal composition each comprising the targeting molecule; a method for treating, examining, diagnosing or monitoring a disease related to the aforesaid target cell; a method for labeling, detecting or imaging the target cell, etc.

Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.

The invention relates to a preparation method of a three-dimensional contraction model for constructing an artificial blood vessel model, and belongs to the technical field of blood vessel models. The method comprises the steps of preparing a collencyte mixed solution, crosslinking and solidifying the collencyte mixed solution, and preparing the three-dimensional contraction model. The prepared three-dimensional contraction model serves as an improved contraction model, adopts myofibroblast IMR-90, grows faster, and is shorter in preparation cycle; auxiliary contraction factors U0126 and TGF-beta are added to stimulate the myofibroblast, so that the three-dimensional contraction model expresses contractive protein, has better contractility, and further has higher mechanical strength; and the prepared three-dimensional contraction model can provide a better and faster contraction model for scientific research, and can provide reference for later clinical application.

The invention belongs to the field of traditional Chinese medicine preparations, and particularly provides a preparation method of kidney nourishing and strengthening capsules.The kidney nourishing and strengthening capsules are prepared by taking 225 g of herba epimedii, 135 g of fructus rosae laevigatae, 135 g of semen cuscutae, 135 g of processed fructus ligustri lucidi and 135 g of processed rhizoma cibotii as bulk pharmaceuticals through supercritical extraction, therefore, the content is greatly increased, and the dosage is decreased.The invention further provides application of the kidney nourishing and strengthening capsules in preparation of a drug for inhibiting proliferation of a human nervous myofibroblast tumor strain SHSY5Y.

The invention discloses high-activity low-temperature plasma, a preparation method and application thereof. The temperature is controlled to be -30 to 300 DEG C under the action of a high-voltage electric field, a working medium is ionized and excited, high-activity low-temperature plasma with the macroscopic temperature close to the room temperature is generated, and the high-activity low-temperature plasma acts on cells and extracellular matrixes; cell membranes are polarized, oxidative stress reaction is caused, extracellular matrix aggregation, fibrosis and myofibroblasts are inhibited, and the regeneration of damaged tissue cells is promoted. The high-activity low-temperature plasma has the characteristics that the high-activity low-temperature plasma comprises oxygen-containing freeradicals and nitrogen-containing free radicals, is wrapped by a working medium, is high in activity, small in particle and high in stability, and can be directly inhaled into a respiratory system. Andas the high-activity low-temperature plasma does not contain other harmful substances and does not pass through other internal organs, no side effect is caused to human bodies.